The biotechnology industry can be a tough one. When trials are a success, a company’s stock flies. However, the opposite can occur when trials get rejected. On Tuesday, the latter happened to Bellerophon Therapeutics. After headlines of the Bellerophon INOpulse trial rejected reached the market, the stock plunged.

Bellerophon INOpulse Trial Rejected: The Facts

Sadly, Bellerophon Therapeutics disclosed today that INOvation-1, its Phase 3 clinical trial, has been rejected, due to its lack of ability to present a treatment effect.

CEO Fabian Tenenbaum put out a statement, announcing that the team is “disappointed in the overall efficacy results” of the INOpulse study. Tenenbaum then thanked “all of the patients and physicians who participated.”

This is sad for two reasons in particular. First, the study was looking at INOpulse in patients suffering from pulmonary arterial hypertension, which is a rare, progressive disorder. Second, this was a Phase 3 study, which means Bellerophon Therapeutics was so close.

So what were the reasons behind the rejection? Well, here’s what the independent Data Monitoring Committee said.

The Independent Data Monitoring Committee

According to the committee, even though the INOpulse treatment demonstrated improvements in PV resistance and there were no urgent safety concerns, the six-minute walk test proved to be insufficient.

Because of this, the committee didn’t see a reason for the continuation of the study and called for the trial to be terminated for futility.

The Bellerophon Therapeutics Stock (NASDAQ:BLPH)

The Bellerophon Therapeutics stock was down in both pre-market trade and early trading, as well at market close.

According to Yahoo Finance, Bellerophon Therapeutics was trading at $0.71 when the closing bell rang, which means the stock closed down 68.86%.

The Company

For those who don’t know, Bellerophon Therapeutics is a Warren, NJ-based company. It focuses primarily on creating products that are made up of novel drugs and devices, all of which can be used to treat cardiopulmonary diseases.

The Takeaway

The Bellerophon INOpulse trial was rejected, but will this lead to the decline of the NJ-based company? I wouldn’t say so. Sure, the more than 60% plunge was unfortunate, but who knows— there’s always next week!

STOCKS YOU MAY LIKE

In the wake of the coronavirus pandemic, biotech stocks have been of interest to investors, given that they’re some of the top gainers in the past few weeks. In particular, low float biotech stocks have …

In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA), which allows the US Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the drug review and approval process. The …

Despite starting the year off strong, biotech stocks have had a rough summer. The recent weakness in the biotech sector is causing biotech exchange-traded funds (ETFs) like the VanEck Vectors Biotech ETF (BBH), the iShares …

We’ve shortlisted four major biotech stocks with upcoming news in April related to FDA decisions. Where will the news take GW Pharmaceuticals (NASDAQ:GWPH), FibroGen (NASDAQ:FGEN), Heron Therapeutics (NASDAQ:HRTX), and Assembly Biosciences (NASDAQ:ASMB)?

Canada is steadily preparing for the national legalization of recreational adult-use cannabis that is set to go into effect in 48 hours. Canadian cannabis companies are scrambling to keep up with the anticipated demand. Due …

Cannabis stocks are on the rise on the Canadian Securities Exchange (CSE) today. Recreational cannabis legalization is less than a week away in Canada, and cannabis stocks have been down all this week. Several companies …